All In Biotech

Drug Trial Radar · NCT02935530

Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

Effectiveness and Safety of Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

Last checked: Nov 20, 2026Latest source record: May 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

315

Actual

Start

Jan 2016

Primary completion

Aug 2017

Study completion Oct 2017

Sponsor

Lead sponsor
Huazhong University of Science and TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Venous thromboembolism (VTE) is an important cause of post-operative morbidity and mortality in women undergoing surgery for gynecologic malignancies. Although the benefit of thromboprophylaxis in reduction of post-operative VTE events after surgery for gynecologic cancers has been well documented around the world, the evidence for Chinese women is rare. The investigators designed this prospective and randomized study to assess the benefit of pharmacologic prophylaxis for patients received surgical treatment for gynecologic malignancies in China.

Conditions

  • Gynecologic Neoplasms
  • Venous Thromboembolism
  • Low Molecular Weight Heparin
  • Argatroban

Interventions

  • s-LMWHDrug

    2125KU, subcutaneous injection of 5-10 days

  • LMWHDrug

    4250KU, subcutaneous injection of 5-10 days

  • ArgatrobanDrug

    20mg, injection for 5-10 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. VTE rateTime frame: 30-days from the date of operation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.